Hyperlipidemia

Statins Beneficial for High-Risk Patients Despite Adverse Reactions

Statins Beneficial for High-Risk Patients Despite Adverse Reactions

By

From 25% to 50% of patients discontinue statins within 6 months to 1 year of starting, and the rate increases as high as 75% after 2 years.

FDA Approves Pitavastatin for Hyperlipidemia, Mixed Dyslipidemia

FDA Approves Pitavastatin for Hyperlipidemia, Mixed Dyslipidemia

By

Multiple clinical studies have examined the efficacy of pitavastatin.

Hydroxychloroquine May Lower Hyperlipidemia Risk in Early Rheumatoid Arthritis

Hydroxychloroquine May Lower Hyperlipidemia Risk in Early Rheumatoid Arthritis

Reduced risk for hyperlipidemia with hydroxychloroquine vs. other disease-modifying antirheumatic drugs.

Fenofibrate May Mimic Cannabinoid Receptor Stimulation

Fenofibrate May Mimic Cannabinoid Receptor Stimulation

By

Researchers have discovered that a common medication indicated for the treatment of high cholesterol may stimulate the same peroxisome proliferator-activated receptors (PPARs) as cannabinoids, which could lead to a new class of cannabis-like drugs to treat a range of conditions.

High Cholesterol in Young Adulthood Heightens CHD Risk

High Cholesterol in Young Adulthood Heightens CHD Risk

By

Young adults with high cholesterol have an increased risk for developing coronary heart disease later in life.

Nurse-Managed Protocols Improved Outpatient Care in Chronic Illnesses

Nurse-Managed Protocols Improved Outpatient Care in Chronic Illnesses

Outcomes positive for nurse-managed protocols in patients with chronic conditions.

Sign Up for Free e-Newsletters

CME Focus